Single-cell Omics Market

Single-cell Omics Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End-User, InstrumentsSingle-cell Omics Market is anticipated to expand from $2.2 billion in 2025 to $7.4 billion by 2035, growing at a CAGR of approximately 12.3%. The single-cell omics market demonstrates a structured pricing hierarchy based on platform type, assay complexity, throughput, and optional add-ons. Entry-level manual low-throughput scRNA/scDNA-seq preparations cost between US$330 and US$420 per sample, making them suitable for small-scale research. Mid-range commercial platforms, including 10x Genomics Chromium single-cell RNA-seq and Parse Biosciences WT kits, are priced between US$1,260 and US$2,250 per sample or kit, depending on library type and multiplexing capabilities. High-end, multiome assays (snRNA-seq + snATAC-seq) and fixed-cell or immune profiling add-ons range from US$3,200 to US$3,750 per sample, reflecting the complexity of multi-omic measurements.

Reagent and library prep kits for 10x Genomics platforms scale with reaction numbers and throughput: small kits (4 reactions) cost around US$2,310$6,487, medium kits (16 reactions) around US$23,588, and very high-throughput kits (48 reactions) reach up to US$55,000 per set. Optional chips and dual-index sets add further costs, typically US$557$1,617 for chips and US$863 for indexing reagents. This structure highlights a clear differentiation between sample-level pricing and batch-scale reagent investment, emphasizing how throughput and assay complexity drive overall costs in the single-cell omics market.

Segment Overview
Based on the type segment, the single-cell omics market is segmented into genomics, transcriptomics, proteomics, and metabolomics. In 2025, genomics accounted for the largest revenue share at USD 953.6 million, driven by its foundational role in detecting DNA-level variation, clonal architecture, and cellular heterogeneity across tissues for disease research and lineage tracing. Transcriptomics is the fastest-growing segment, with innovations in scRNA-seq enabling identification of rare cell types, differentiation trajectories, and dynamic expression patterns in cancer, immunology, and developmental studies. Proteomics and metabolomics are also expanding due to advances in protein quantification and metabolic profiling, contributing to multimodal integration for deeper insights into disease mechanisms and therapeutic responses.

Based on the product segment, the single-cell omics market is segmented into instruments, consumables & reagents, and software & services. In 2025, consumables & reagents accounted for the largest revenue share at USD 1,091.9 million, driven by high-throughput needs in genomic and transcriptomic studies and NIH-funded projects highlighting their critical role in single-cell analysis. Software & services is the fastest-growing segment, fueled by AI integration for multi-omics data analysis, exemplified by Majorbio Clouds 2024 release of single-omics workflows accelerating bioinformatics discoveries. Instruments also contribute to growth through advanced sequencers, microfluidics, and initiatives like the Single Cell Analysis Program supporting tumor heterogeneity and cellular atlas projects.

Geographical Overview
The global single-cell omics market demonstrates clear regional variation in 2025, with North America emerging as the largest regional market at approximately $967.3 million. Growth is primarily driven by the United States, which benefits from strong research funding, a high concentration of leading genomics companies, and large-scale collaborative initiatives supporting advanced single-cell research. Strategic partnerships, such as industryclinical laboratory collaborations, are accelerating atlas-scale projects and translational research. Canada further strengthens regional growth through significant government investments aimed at expanding genome sequencing capabilities and enabling personalized, preventive healthcare, while Mexico remains a smaller contributor but shows long-term potential through institutional capacity building and scientific talent development.

Asia-Pacific generates around $488.9 million in 2025 and stands out as the fastest-growing region, supported by Chinas expanding single-cell research infrastructure, Japans leadership in advanced single-cell technologies, and Indias rapid laboratory development through academicindustry partnerships. Additional momentum comes from rising government investments in biological data platforms in South Korea, expanded omics grant funding in Australia, and precision medicine initiatives in Singapore and Southeast Asia. Europe records about $592.1 million in 2025, driven by large EU-funded genomics programs, strong CRO presence, and cross-border collaborations, while Latin America and the Middle East & Africa show steady growth, led by Brazil and Saudi Arabia, respectively, through national genomics and precision medicine initiatives.

Key Trends and Drivers
Innovations Driving Single-Cell Analysis
Rising demand for high-throughput single-cell profiling is pushing innovation toward scalable, automated, and multiomic technologies. The launch of 10x Genomics next-generation Flex assay in October 2025, enabling analysis of up to 100 million cells per week, highlights the shift toward large-volume studies such as CRISPR screens and translational research. Expansion of integrated CRISPR-based workflows, including Illuminas Perturb-seq solution introduced in February 2025, reflects growing interest in multimodal, high-resolution analysis. Meanwhile, cost-efficient tools like Bio-Rads ddSEQ 3 RNA-Seq Kit and advanced proteomics platforms such as Standard BioTools CyTOF XT PRO are improving accessibility and accelerating discovery across oncology, immunology, and precision medicine.

Accelerating Automation to Strengthen Single-Cell Omics Workflows
Automation is a key driver as laboratories seek faster, reproducible, and scalable single-cell workflows. In October 2025, BD and Opentrons launched robotics-enabled solutions supporting million-cell studies, demonstrating strong momentum toward automated platforms. Partnerships such as BD and Hamiltons automation-ready reagents (October 2024) reduce manual errors and improve consistency. Fully automated systems like Singleron and Hamiltons Tensor platform, launched in April 2025, enable high-throughput multiomics sequencing. Advances in cell isolation, including iotaSciences scPicking Platform, and studies showing 75% reductions in hands-on time further reinforce demand for automated, end-to-end single-cell omics solutions.

RECENT DEVELOPMENTS
In October 2025, 10x Genomics partnered with Anthropic to integrate single-cell and spatial analysis tools into Claude for Life Sciences, enabling conversational interaction with complex datasets, reducing computational barriers, and making advanced biological insights more accessible to researchers.

In October 2025, 10x Genomics launched the next-generation Chromium Flex assay, enabling ultra-high-throughput single-cell analysis through plate-based multiplexing, allowing researchers to process hundreds of samples and millions of cells weekly with improved automation, scalability, and cost efficiency.

In June 2025, Bruker unveiled the timsUltra AIP mass spectrometer at ASMS 2025, featuring the Athena Ion Processor to significantly enhance sensitivity and protein identification, strengthening applications in single-cell proteomics, immunopeptidomics, and metaproteomics research.

In April 2025, Standard BioTools introduced major proteomics upgrades at AACR 2025, including the SomaScan Select 3.7K Assay, Single SOMAmer reagents, and the enhanced CyTOF XT PRO system, expanding high-plex protein analysis for translational and oncology research.

In February 2025, Illumina expanded its multiomics portfolio with new technologies spanning genomics, spatial transcriptomics, single-cell analysis, CRISPR, and methylation, launching advanced multimodal data analysis solutions to accelerate disease research, gene expression studies, and therapeutic discovery.

KEY PLAYERS
10x Genomics, Illumina Inc., Standard BioTools Inc., Thermo Fisher Scientific Inc., Precision Cell Systems Inc., Bio-Rad Laboratories Inc., Precigenome LLC, Becton Dickinson and Company (BD), Pacific Biosciences, Menarini Group, PerkinElmer, Takara Bio, Bruker, Danaher Corporation (Cytiva), QIAGEN (Parse Biosciences), Zifo, Mission Bio, BICO (Cellenion), CelLBxHealth (ANGLE plc), Creative Biolabs

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation. Show more